Brainsway (BWAY) Competitors $15.77 +0.07 (+0.45%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.80 +0.03 (+0.16%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BWAY vs. ESTA, MDXG, PLSE, INMD, IRMD, BBNX, EMBC, KMTS, TNDM, and AXGNShould you be buying Brainsway stock or one of its competitors? The main competitors of Brainsway include Establishment Labs (ESTA), MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Beta Bionics (BBNX), Embecta (EMBC), Kestra Medical Technologies (KMTS), Tandem Diabetes Care (TNDM), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry. Brainsway vs. Its Competitors Establishment Labs MiMedx Group Pulse Biosciences InMode iRadimed Beta Bionics Embecta Kestra Medical Technologies Tandem Diabetes Care AxoGen Establishment Labs (NASDAQ:ESTA) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Do insiders and institutionals believe in ESTA or BWAY? 72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 11.4% of Establishment Labs shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, ESTA or BWAY? Brainsway has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstablishment Labs$166.02M6.54-$84.60M-$3.05-12.29Brainsway$41.02M7.27$2.92M$0.2660.65 Do analysts recommend ESTA or BWAY? Establishment Labs presently has a consensus target price of $56.50, indicating a potential upside of 50.79%. Brainsway has a consensus target price of $18.00, indicating a potential upside of 14.14%. Given Establishment Labs' higher probable upside, analysts clearly believe Establishment Labs is more favorable than Brainsway.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Establishment Labs 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Brainsway 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ESTA or BWAY? In the previous week, Establishment Labs had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Establishment Labs and 3 mentions for Brainsway. Establishment Labs' average media sentiment score of 1.25 beat Brainsway's score of 1.19 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ESTA or BWAY? Establishment Labs has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Is ESTA or BWAY more profitable? Brainsway has a net margin of 11.60% compared to Establishment Labs' net margin of -49.89%. Brainsway's return on equity of 8.97% beat Establishment Labs' return on equity.Company Net Margins Return on Equity Return on Assets Establishment Labs-49.89% -224.34% -25.53% Brainsway 11.60%8.97%5.65% SummaryBrainsway beats Establishment Labs on 10 of the 16 factors compared between the two stocks. Get Brainsway News Delivered to You Automatically Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BWAY vs. The Competition Export to ExcelMetricBrainswayMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$298.05M$10.65B$5.78B$10.18BDividend YieldN/A1.88%5.73%4.60%P/E Ratio60.6621.5175.4626.02Price / Sales7.2730.96464.4091.13Price / Cash63.2225.0025.8129.91Price / Book4.763.5212.166.25Net Income$2.92M$210.63M$3.29B$270.76M7 Day Performance-0.82%0.34%0.73%2.54%1 Month Performance21.49%2.66%4.41%5.73%1 Year Performance91.85%-10.98%62.61%25.85% Brainsway Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BWAYBrainsway3.5759 of 5 stars$15.77+0.4%$18.00+14.1%+91.8%$298.05M$41.02M60.66120Positive NewsShort Interest ↑ESTAEstablishment Labs2.2799 of 5 stars$38.24-2.0%$56.50+47.8%-15.2%$1.13B$166.02M-12.541,018Positive NewsMDXGMiMedx Group3.496 of 5 stars$7.17+0.4%$12.00+67.4%+11.6%$1.06B$348.88M34.14870Positive NewsPLSEPulse Biosciences4.334 of 5 stars$15.04-0.5%$22.00+46.3%-21.6%$1.02B$700K-14.32140Positive NewsInsider TradeINMDInMode3.1018 of 5 stars$15.28+2.0%$18.04+18.1%-13.0%$946.87M$401.56M6.19480Positive NewsIRMDiRadimed4.8176 of 5 stars$71.85-0.2%$72.00+0.2%+47.0%$915.36M$73.24M44.35110Short Interest ↓BBNXBeta Bionics1.0293 of 5 stars$23.13+14.5%$22.56-2.5%N/A$878.10M$65.12M0.00294High Trading VolumeEMBCEmbecta4.5241 of 5 stars$14.65-2.1%$19.00+29.7%-6.3%$874.94M$1.12B10.242,100Positive NewsKMTSKestra Medical Technologies1.7069 of 5 stars$17.86+5.1%$27.33+53.0%N/A$872.93M$59.81M0.00300Positive NewsGap UpTNDMTandem Diabetes Care4.4784 of 5 stars$12.50-0.6%$22.44+79.5%-72.1%$850.02M$940.20M-4.052,650Positive NewsAXGNAxoGen2.6469 of 5 stars$16.04+0.4%$26.00+62.1%+19.0%$735.28M$187.34M-160.38450Positive News Related Companies and Tools Related Companies ESTA Alternatives MDXG Alternatives PLSE Alternatives INMD Alternatives IRMD Alternatives BBNX Alternatives EMBC Alternatives KMTS Alternatives TNDM Alternatives AXGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BWAY) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainsway Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainsway With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
